

FORM 8 (OPD)

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER
Rules 8.1 and 8.2 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Full name of discloser:	Alliance Pharma plc
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): <i>The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.</i>	N/A
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: <i>Use a separate form for each offeror/offeree</i>	Alliance Pharma plc
(d) Is the discloser the offeror or the offeree?	Offeree
(e) Date position held: <i>The latest practicable date prior to the disclosure</i>	16 January 2025
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? <i>If it is a cash offer or possible cash offer, state "N/A"</i>	N/A

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

Class of relevant security:	Ordinary shares of 1 pence each			
	Interests		Short positions	
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	Nil	-	Nil	-
(2) Cash-settled derivatives:	Nil	-	Nil	-
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:	Nil	-	Nil	-
TOTAL:	Nil	-	Nil	-

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

(b) Rights to subscribe for new securities

Class of relevant security in relation to which subscription right exists:	N/A
Details, including nature of the rights	...

concerned and relevant percentages:	N/A
-------------------------------------	-----

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

Interests of directors

Alliance Pharma plc ordinary shares held by directors of Alliance Pharma plc:

Director	Number of Alliance Pharma plc ordinary shares held	Percentage of total issued share capital
Andrew Franklin	192,911	0.03%
Richard Jones	68,000	0.01%

Interests held as options or awards by directors of Alliance Pharma plc in ordinary shares of Alliance Pharma plc:

Director	Share Plan	Grant date	No. of Alliance Pharma plc ordinary shares in respect of which options granted/subject to award	Expiry date	Vesting date	Exercise price per share (£)
Andrew Franklin	LTIP Award	29 September 2022	188,505	29 September 2026	29 September 2025 (subject to performance conditions)	Nil
	LTIP Award	4 October 2023	568,866	4 October 2027	4 October 2026 (subject to performance conditions)	Nil
	Unapproved Share Options	4 December 2015	500,000	4 December 2025	4 December 2018	0.4675
	Unapproved Share Options	27 October 2016	155,000	27 October 2026	27 October 2019	0.4750
	Unapproved Share Options	27 October 2016	400,000	27 October 2026	27 October 2021	0.4750
	CSOP Unapproved Options	15 September 2017	170,000	15 September 2027	15 September 2020	0.53
	CSOP Unapproved Options	5 October 2018	178,000	5 October 2028	5 October 2021	0.8160
	CSOP Approved Options	5 December 2019	19,506	5 December 2029	5 December 2022	0.7690
	CSOP Unapproved Options	5 December 2019	27,995	5 December 2029	5 December 2022	0.7690
	CSOP Unapproved Options	29 September 2022	121,900	29 September 2032	29 September 2025	0.5820
Nick Sedgwick	LTIP Award	24 June 2024	906,862	N/A	24 June 2027	Nil

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it: <i>Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"</i>
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: <i>If there are no such agreements, arrangements or understandings, state "none"</i>
None

(c) Attachments

Are any Supplemental Forms attached?

Supplemental Form 8 (Open Positions)	No
Supplemental Form 8 (SBL)	No

Date of disclosure:	17 January 2025
Contact name:	Chris Chrysanthou, Group Company Secretary
Telephone number:	+44 (0)1249 591078

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

FEESFLFWWEISEFF